Evidence map›Paper›PMID 40457437›Full record

ReviewMolecular cancer2025

Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery.

Hussein Sabit, Timothy M Pawlik, Faisal Radwan, Mohamed Abdel-Hakeem, Shaimaa Abdel-Ghany, Al-Hassan Soliman Wadan, Mokhtar Elzawahri, Ahmed El-Hashash, Borros Arneth

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hussein SabitDepartment of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza, Egypt. hussein.sabit@must.edu.eg.
Timothy M PawlikDepartment of Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, 43210, USA. tim.pawlik@osumc.edu.
Faisal RadwanCenter for Coastal Environmental Health and Biomolecular Research, NCCOS/NOS/NOAA, Charleston, SC, 29412, USA.
Mohamed Abdel-HakeemDepartment of Pharmaceutical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza, Egypt.
Shaimaa Abdel-GhanyDepartment of Environmental Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza, Egypt.
Al-Hassan Soliman WadanOral Biology Department, Faculty of Dentistry, Galala Plateau, Galala University, Suez Governorate, Attaka, 15888, Egypt.
Mokhtar ElzawahriDepartment of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, P.O. Box 77, Giza, Egypt.
Ahmed El-HashashElizabeth City State Campus of the University of North Carolina (UNC), Elizabeth, USA.
Borros ArnethInstitute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Hospital of the Universities of Giessen and Marburg (UKGM), Philipps University Marburg, Baldingerstr. 1, 35043, Marburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment has been revolutionized by immunotherapy and nanomedicine, offering innovative strategies to overcome the tumor microenvironment (TME) complexities. However, challenges such as therapeutic resistance, off-target effects, and immune suppression necessitate advanced delivery systems and combination approaches. Recent advancements in nanoparticle-based therapies, biomimetic platforms, and personalized immunotherapy provide promising solutions to enhance therapeutic efficacy while minimizing systemic toxicity. This review explores recent nanoparticle-mediated immunotherapy developments, highlighting strategies to optimize drug delivery, remodel the TME, and improve patient-specific treatment outcomes. A comprehensive review of recent literature focused on nanoparticle-based drug delivery, stimuli-responsive systems, biomimetic nanoplatforms, and personalized immunotherapy approaches. The effectiveness of combination therapies integrating physical and immunological strategies was also analyzed. Nanoparticle-mediated immunotherapy enables precise targeting and controlled drug release, significantly improving therapeutic outcomes. Biomimetic nanoplatforms enhance immune modulation and drug bioavailability, while personalized immunotherapy, guided by predictive biomarkers, tailors treatment to individual patients. Advanced nanomedicine strategies, including TME remodeling, targeted genome editing, and combination immunotherapies, offer promising avenues for overcoming limitations in conventional cancer treatments. Future research should optimize nanoformulations, integrate multi-modal treatment strategies, and refine biomarker-driven personalization to enhance clinical outcomes.

Indexed as

Drug Delivery SystemsImmunotherapyNanomedicineNeoplasmsPrecision MedicineTumor MicroenvironmentAnimalsHumansNanoparticlesCancer therapyDrug deliveryImmunotherapyNanomedicineTumor microenvironment

Identifiers

PMID40457437
PMCPMC12131435

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.